efgitasialase alfa + rituximab

efgitasialase alfa + rituximab (HLX79 + Hanlikang) is an investigational combination therapy consisting of efgitasialase alfa (E-602 / HLX79), a first-in-class recombinant human sialidase fusion protein, and Hanlikang (HLX01), a rituximab biosimilar targeting CD20. Developed through a collaboration between Palleon Pharmaceuticals and Henlius, this combination is designed to treat autoimmune kidney diseases, specifically active glomerulonephritis (including lupus nephritis and membranous nephropathy). Efgitasialase alfa enzymatically cleaves terminal sialic acid residues from sialoglycans on the surface of pathogenic immune cells, such as memory B cells and M2-like macrophages. This desialylation removes glycan-mediated immunosuppressive signals, thereby enhancing rituximab-mediated B-cell depletion and reducing pro-fibrotic macrophages. The combination is currently being evaluated in Phase 2 clinical trials in China.

Other names

E-602 + HanlikangE-602 + rituximabE-602 plus HanlikangE602 plus HanlikangE 602 plus HanlikangE-602 plus rituximabE602 plus rituximabE 602 plus rituximabHLX79 + HanlikangHLX79 + rituximabHLX79 plus HanlikangHLX-79 plus HanlikangHLX 79 plus HanlikangHLX79 plus rituximabHLX-79 plus rituximabHLX 79 plus rituximabefgitasialase alfa + Hanlikangefgitasialase alfa plus Hanlikangefgitasialase alfa plus rituximab